Ira Gantz

8PUBLICATIONS
14CO-AUTHORS
Food properties (incl. characteristics and health benefits)PharmacogenomicsMolecular targetsPharmaceutical delivery technologiesSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.

Francesco Cosentino, Samuel Dagogo-Jack, Robert Frederich

|Jan 29, 2021
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.

Takashi Kadowaki, Yutaka Seino, Kohei Kaku

|Nov 06, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.

Ronan Roussel, Santiago Duran-García, Yilong Zhang

|Nov 08, 2017
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

Seung-Hwan Lee, Ira Gantz, Elizabeth Round

|Sep 13, 2017
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Ira Gantz, Menghui Chen, Shailaja Suryawanshi

|Jun 08, 2017
A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.

Ira Gantz, Taro Okamoto, Yuka Ito

Pageof 2

Frequent Collaborators

2 joint publications

Samuel S Engel

1 joint publications

Ronan Roussel

1 joint publications

Kohei Kaku

1 joint publications

Taro Okamoto